Literature DB >> 17592596

A spiro to ansa rearrangement in cyclotriphosphazene derivatives.

Serap Beşli1, Simon J Coles, David B Davies, Michael B Hursthouse, Adem Kiliç, Robert A Shaw.   

Abstract

Nucleophilic substitution reactions of cyclotriphosphazene derivatives having five-membered spiro rings, N(3)P(3)Cl(4)[O(CH(2))(2)X] (X = NH or O) with alkoxides (of tetraethylene glycol and some mono-functional alcohols) give unexpected rearrangements to form stable seven-membered ring ansa compounds, even though crystallographic evidence shows ring distortion and compression of the cyclophosphazene ring. With weaker nucleophiles such as sodium phenoxide and pyrrolidine substitution at a PCl2 group is preferred and no rearrangement takes place. In contrast, reactions of the analogous phosphazenes containing six-membered spiro rings, N(3)P(3)Cl(4)[O(CH(2))(3)X], with all of the above reagents give only normal substitution reactions at the PCl2 moieties and no rearrangement products. The spiro to ansa rearrangements in cyclophosphazenes are remarkable as the reported primary reaction products with the same difunctional reagents HO(CH(2))(2)XH are predominantly spiro, with some dangling and bridging derivatives, but no ansa compounds.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17592596     DOI: 10.1039/b703541a

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  2 in total

1.  4',4',6',6'-Tetra-chloro-2-(6-methyl-pyridin-2-yl)-1H,2H-spiro-[naphtho-[1,2-e][1,3,2]oxaza-phosphinine-3,2'-[1,3,5,2,4,6]tri-aza-triphosphinine].

Authors:  Muhammet Işıklan; Omer Sonkaya; Tuncer Hökelek
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-05-11

2.  2-(4-Methyl-pyridin-2-yl)-4',4',6',6'-tetra-kis-(pyrrolidin-1-yl)-1H,2H-spiro-[naphtho-[1,2-e][1,3,2]oxaza-phosphinine-3,2'-[1,3,5,2,4,6]tri-aza-triphosphinine].

Authors:  Muhammet Işıklan; Omer Sonkaya; Tuncer Hökelek
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.